CLEC10A and malignant colon neoplasm: Furthermore, we demonstrate that expression of MGL ligands is associated with poor survival and disease recurrence, in particular in stage III but not in stage II colon cancer patients, independent of MSI status or treatment with adjuvant chemotherapy.